The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Rgenix
Phase I monotherapy dose escalation of RGX-202, a first-in-class oral inhibitor of the SLC6a8/CKB pathway, in patients with advanced gastrointestinal (GI) solid tumors.
 
Johanna C. Bendell
Consulting or Advisory Role - Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Bicycle Therapeutics (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cerulean Pharma (Inst); Continuum Clinical (Inst); Cyteir (Inst); Daiichi Sankyo (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Innate Pharma (Inst); Ipsen (Inst); Janssen (Inst); Kyn therapeutics (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Merrimack (Inst); Moderna Therapeutics (Inst); Molecular Partners (Inst); Novartis (Inst); Oncogenex (Inst); OncoMed (Inst); Phoenix Biotech (Inst); Prelude Therapeutics (Inst); Relay Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tanabe Research (Inst); TD2 (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Tolero Pharmaceuticals (Inst); Torque (Inst)
Research Funding - Abbott/AbbVie (Inst); Acerta Pharma (Inst); ADC Therapeutics (Inst); Agios (Inst); Amgen (Inst); Apexigen (Inst); Arch Oncology (Inst); Arcus Biosciences (Inst); ARMO BioSciences (Inst); Array BioPharma (Inst); Arrys Therapeutics (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bellicum Pharmaceuticals (Inst); Bicycle Therapeutics (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); cyteir (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); eFFECTOR Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); EMD Serono (Inst); Evelo Therapeutics (Inst); Evelo Therapeutics (Inst); Five Prime Therapeutics (Inst); FORMA Therapeutics (Inst); Forty Seven (Inst); Forty Seven (Inst); Genentech/Roche (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Gossamer Bio (Inst); Gritstone Bio (Inst); Harpoon therapeutics (Inst); Harpoon therapeutics (Inst); ImClone Systems (Inst); Incyte (Inst); Innate Pharma (Inst); Innate Pharma (Inst); Ipsen (Inst); Jacobio (Inst); Janssen (Inst); Kolltan Pharmaceuticals (Inst); Leap Therapeutics (Inst); Lilly (Inst); Macrogenics (Inst); Marshall Edwards (Inst); Merck (Inst); Merrimack (Inst); Mersana (Inst); Merus (Inst); Millenium Pharamceuticals (Inst); Molecular Partners (Inst); Nektar (Inst); Novartis (Inst); Novocure (Inst); Oncogenex (Inst); OncoMed (Inst); Onyx (Inst); Pfizer (Inst); Phoenix Biotech (Inst); Pieris Pharmaceuticals (Inst); Prelude Therapeutics (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Rgenix (Inst); Sanofi (Inst); Seagen (Inst); Shattuck Labs (Inst); Sierra Oncology (Inst); Sorrento Therapeutics (Inst); Stem CentRx (Inst); SynDevRx (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tempest Therapeutics (Inst); TG Therapeutics (Inst); Tizona Therapeutics, Inc. (Inst); Torque (Inst); TRACON Pharma (Inst); Tyrogenex (Inst); Unum Therapeutics (Inst); Vyriad (Inst); Zymeworks (Inst)
Travel, Accommodations, Expenses - ARMO BioSciences; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; FORMA Therapeutics; Gilead Sciences; Ipsen; Lilly; MedImmune; Merck; Novartis; OncoMed; Roche/Genentech; Taiho Pharmaceutical
 
James Fredric Strauss
Employment - Dialectic Therapeutics
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Bristol-Myers Squibb; Intuitive Surgical; Johnson & Johnson; Merck
Consulting or Advisory Role - Tempus
Other Relationship - Dialectic Therapeutics
 
Marwan Fakih
Consulting or Advisory Role - Amgen; Array BioPharma; Genentech/Roche
Speakers' Bureau - Amgen; Taiho Pharmaceutical
Research Funding - Amgen (Inst); AstraZeneca (Inst); Novartis (Inst)
 
Autumn Jackson McRee
Research Funding - Boston Biomedical (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst); Merck (Inst); Novartis (Inst)
 
Andrew Eugene Hendifar
Consulting or Advisory Role - Abbvie; Celgene; Ipsen; Novartis; Perthera
Research Funding - Ipsen
Travel, Accommodations, Expenses - Halozyme
 
Lee S. Rosen
Research Funding - Bayer (Inst); CytomX Therapeutics (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Rgenix (Inst)
 
Andrea Cercek
Consulting or Advisory Role - Array Biopharma; Bayer; Proteus Digital Health
Research Funding - Abbvie; Seagen; Tesaro
 
Eric Keith Rowinsky
Employment - Rgenix
Leadership - Rgenix
Stock and Other Ownership Interests - Rgenix
 
Michael Szarek
Employment - Rgenix
Stock and Other Ownership Interests - Rgenix
Consulting or Advisory Role - CiVi Biopharma; Esperion Therapeutics; Regeneron; Resverlogix; Sanofi; Spectrum Pharmaceuticals
Research Funding - Regeneron; Sanofi
Expert Testimony - Regeneron; Sanofi
 
Foster Gonsalves
Employment - Rgenix
Stock and Other Ownership Interests - Rgenix
 
Isabel Kurth
No Relationships to Disclose
 
Celia Andreu
Employment - Rgenix
Stock and Other Ownership Interests - Rgenix
 
Robert Busby
Employment - Rgenix
Stock and Other Ownership Interests - Rgenix
 
Scott Spector
Employment - Johnson & Johnson (I); Rgenix
Stock and Other Ownership Interests - Acadia Pharmaceuticals; Amarin Corporation; Exelixis; Fortress Biotech; Humana; Merck; MustangBio; Rgenix; Stemline Therapeutics; Verastem
Consulting or Advisory Role - Bionest partners; Erytech Pharma; Fortress Biotech; INC Research; Lokon Pharma; OncoTartis; Pharnext; Premier Research
 
David Martin Darst
Employment - Rgenix
Leadership - Rgenix
Stock and Other Ownership Interests - Apellis Pharmaceuticals; Rgenix
Consulting or Advisory Role - PSP investments
 
Masoud Tavazoie
Employment - Rgenix
Leadership - Rgenix
Stock and Other Ownership Interests - Rgenix
 
Syed Raza
Employment - Rgenix
 
Narayan Lebaka
Employment - Rgenix
Stock and Other Ownership Interests - Rgenix
 
Robert Wasserman
Employment - Northern Biologics; Rgenix
Leadership - Northern Biologics; Rgenix
Stock and Other Ownership Interests - Northern Biologics; Rgenix; Roche/Genentech; Sectoral Asset Management
Consulting or Advisory Role - Sectoral Asset Management
Travel, Accommodations, Expenses - Northern Biologics; Rgenix
 
Yelena Yuriy Janjigian
Consulting or Advisory Role - Bristol-Myers Squibb; Daiichi Sankyo; Jounce Therapeutics; Lilly; Merck; Merck Serono; Michael J. Hennessy Associates; Ono Pharmaceutical; Pfizer; Rgenix
Research Funding - Amgen; Bayer; Boehringer Ingelheim; Genentech; Lilly; Roche